An Open-Label, Dose Escalation, Phase I Safety, and Immunogenicity Trial of a Dengue Serotype 1 (DEN-1) Premembrane (prM) and Envelope (E) DNA Vaccine (D1ME100) in Healthy Adults Volunteers
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Dengue DNA vaccine (Primary)
- Indications Dengue
- Focus Adverse reactions
- 07 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jul 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 25 Nov 2006 New trial record.